AVEO Pharmaceuticals Inc is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted medicines for oncology and other areas of unmet medical need. The Company aim is to retain North American rights to its oncology portfolio while securing partners in development and commercialization outside of North America. It is seeking to develop and commercialize its lead candidate tivozanib in North America as a treatment for advanced or metastatic renal cell carcinoma (RCC). It has outlicensed tivozanib (FOTIVDA) for oncology in Europe and other territories outside North America.
| Website: | www.aveooncology.com |
| Email: | aveo@argotpartners.com |
| Main Phone: | +1 617 588-1960 |
| Address: | One Broadway |
| Address 2: | 14th Floor |
| State: | MA |
| City / Town: | Cambridge |
| Country: | USA |
| Postal Code: | 02142 |
| Exchange: | NSC |
| CEO: | Michael P. Bailey |
| Employees: | 17 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Gathering Data... Please wait AVEO Pharmaceuticals Inc is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted medicines for oncology and other areas of unmet medical need. The Company aim is to retain North American rights to its oncology portfolio while securing partners in development and commercialization outside of North America. It is seeking to develop and commercialize its lead candidate tivozanib in North America as a treatment for advanced or metastatic renal cell carcinoma (RCC). It has outlicensed tivozanib (FOTIVDA) for oncology in Europe and other territories outside North America.
| Website: | www.aveooncology.com |
| Email: | aveo@argotpartners.com |
| Main Phone: | +1 617 588-1960 |
| Address: | One Broadway |
| Address 2: | 14th Floor |
| State: | MA |
| City / Town: | Cambridge |
| Country: | USA |
| Postal Code: | 02142 |
| Exchange: | NSC |
| CEO: | Michael P. Bailey |
| Employees: | 17 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
| Last Price 0.61 | Change $ 0.0199 | Change % 3.37 | Tick N/A |
| Bid 0.61 | Bid Size 3,000.00 | Ask 0.63 | Ask Size 500.00 |
| Open 0.60 | High 0.62 | Low 0.57 | Prev Close 0.59 |
| Last Trade | Volume 1.7 mi | 52 Wk Hi 3.59 | 52 Wk Low 0.49 |
| Market Cap 84.8 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 139,000,340.00 | EPS (TTM) -0.28 | PE Ratio N/A | Exchange NCM |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 72 | 74 |
| Number of Buys | 72 | 72 |
| Number of Sells | 0 | 2 |
| Net Activity | 11057427 | 11005613 |
| Last 10 Buys | Shares |
|---|---|
| David M. Mott | 1,000 |
| Peter Sonsini | 1,000 |
| Jon Sakoda | 1,000 |
| Forest Baskett | 1,000 |
| Sandell D Scott | 1,000 |
| Anthony A. Florence | 1,000 |
| Peter J. Barris | 1,000 |
| Ravi Viswanathan | 1,000 |
| Joshua Makower | 1,000 |
| Ravi Viswanathan | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Matthew Dallas | 1,000 |
| Michael P. Bailey | 1,000 |
| Matthew Dallas | 1,000 |
| Joseph Vittiglio | 1,000 |
| Jeno Gyuris | 1,000 |
| Joseph Vittiglio | 1,000 |
| Jeno Gyuris | 1,000 |
| William Slichenmyer | 1,000 |
| Michael P. Bailey | 1,000 |
| David Johnston | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 7 | 7 | 7 | 7 |
| Low Target Price Estimate | 5 | 5 | 5 | 5 |
| Mean Target Price Estimate | 5.67 | 5.67 | 5.67 | 5.67 |
| Standard Deviation | 1.15 | 1.15 | 1.15 | 1.15 |
| Date of Most Recent Estimate | 05/08/18 | 05/08/18 | 05/08/18 | 05/08/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-30 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-30 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-30 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-30 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-30 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-30 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-30 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-30 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-30 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-30 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1 | 1 | 1 | 1 |
© 2019 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
